Quick Answer
VYNE Therapeutics Inc. reported Operating Income of -$29.75 million for fiscal year 2025.
VYNE Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$29.75M | +31.8% |
| 2024 | -$43.64M | -49.1% |
| 2023 | -$29.26M | +14.7% |
| 2022 | -$34.30M | +11.9% |
| 2021 | -$38.91M | +84.6% |
| 2020 | -$252.55M | -163.4% |
| 2019 | -$95.87M | -28.0% |
| 2018 | -$74.89M | -153.1% |
| 2017 | -$29.59M | -106.5% |
| 2016 | -$14.33M | -211.0% |
| 2015 | -$4.61M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$7.54M | +27.5% | +18.0% |
| March 31, 2025 | -$9.20M | -24.6% | +29.7% |
| September 30, 2024 | -$13.09M | -110.0% | -25.9% |
| June 30, 2024 | -$10.40M | -0.8% | -40.9% |
| March 31, 2024 | -$7.38M | -25.6% | -18.4% |
| September 30, 2023 | -$6.23M | +33.2% | +39.6% |
| June 30, 2023 | -$10.32M | -24.5% | -75.6% |
| March 31, 2023 | -$5.88M | +32.4% | +37.1% |
- VYNE Therapeutics Inc. showed an increase of +31.8% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, VYNE Therapeutics Inc.’s operating income has declined by 545.6% (from -$4.61 million to -$29.75 million).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: